213 related articles for article (PubMed ID: 14529382)
1. Overview: translating Hsp90 biology into Hsp90 drugs.
Workman P
Curr Cancer Drug Targets; 2003 Oct; 3(5):297-300. PubMed ID: 14529382
[TBL] [Abstract][Full Text] [Related]
2. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
Maloney A; Workman P
Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
[TBL] [Abstract][Full Text] [Related]
3. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
Workman P
Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
[TBL] [Abstract][Full Text] [Related]
5. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
7. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
8. Altered states: selectively drugging the Hsp90 cancer chaperone.
Workman P
Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
[TBL] [Abstract][Full Text] [Related]
9. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
11. Hsp90: an emerging target for breast cancer therapy.
Beliakoff J; Whitesell L
Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
[TBL] [Abstract][Full Text] [Related]
12. Altered Hsp90 function in cancer: a unique therapeutic opportunity.
Bagatell R; Whitesell L
Mol Cancer Ther; 2004 Aug; 3(8):1021-30. PubMed ID: 15299085
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 as a therapeutic target in prostate cancer.
Solit DB; Scher HI; Rosen N
Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
15. The Hsp90 chaperone complex as a novel target for cancer therapy.
Goetz MP; Toft DO; Ames MM; Erlichman C
Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
[TBL] [Abstract][Full Text] [Related]
16. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
17. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
18. Antimyeloma activity of heat shock protein-90 inhibition.
Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
[TBL] [Abstract][Full Text] [Related]
19. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
20. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
Gossett DR; Bradley MS; Jin X; Lin J
Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]